Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03684018
PHASE4

Two Dose Levels of Privigen in Pediatric CIDP

Sponsor: CSL Behring

View on ClinicalTrials.gov

Summary

A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment

Official title: Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP

Key Details

Gender

All

Age Range

2 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2019-02-28

Completion Date

2029-12-20

Last Updated

2025-10-20

Healthy Volunteers

No

Interventions

BIOLOGICAL

IgPro10

Normal human immunoglobulin G administered intravenously

Locations (9)

Phoenix Children's Hospital

Phoenix, Arizona, United States

Children's Hospital of Los Angeles

Los Angeles, California, United States

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Akron Children's Hospital

Akron, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Le Bonheur Children's Hospital

Memphis, Tennessee, United States

Neurology Rare Disease Center

Denton, Texas, United States

Children's Specialty Group

Norfolk, Virginia, United States

Seattle Children's Hospital

Seattle, Washington, United States